Drugs / CAR-BCMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05243212 | Sep 2021 → Sep 2024 overdue | plasma cell myeloma | Sheba Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-BCMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05243212 ↗ |
| Action | Deplete | “CAR-BCMA T-cells identify and eliminate BCMA-expressing malignant plasma cells.” NCT05243212 ↗ |
| Modality | Cell therapy | “genetically modified autologous T-cells” NCT05243212 ↗ |